Evidence map›Paper›PMID 42498834›Full record

Trial reportLeukemia2026

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

Hagop Kantarjian, Michael Deininger, Jane F Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H Lipton, Elza Lomaia, James McCloskey and 13 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02467270 (A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02467270 phase2completednot on this map

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

TypeinterventionalSponsorTakedaRan2015 to 2025Enrolled283ConditionsMyeloid Leukemia, Chronic, Chronic PhaseArmsPonatinib
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hagop KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. hkantarjian@mdanderson.org.ORCID http://orcid.org/0000-0002-1908-3307
Michael DeiningerUniversity of Michigan Ann Arbor, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-2987-1331
Jane F ApperleyImperial College London, London, UK.ORCID http://orcid.org/0000-0002-1710-1794
Christopher Kevin ArthurRoyal North Shore Hospital, St. Leonards, NSW, Australia.ORCID http://orcid.org/0000-0002-9147-9090
Charles ChuahSingapore General Hospital, Duke-NUS Medical School, Singapore, Singapore.
Andreas HochhausUniversitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-0626-0834
Hugues de LavalladeGuy's and St Thomas' NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-4988-2564
Jeffrey H LiptonPrincess Margaret Cancer Centre, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7391-7168
Elza LomaiaAlmazov National Medical Research Centre, St. Petersburg, Russia.ORCID http://orcid.org/0000-0003-3290-7961
James McCloskeyThe John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ, USA.
Lori ManessUniversity of Nebraska Medical Center, Omaha, NE, USA.
Michael MauroMemorial Sloan Kettering, New York, NY, USA.ORCID http://orcid.org/0000-0002-2251-4032
Beatriz MoiraghiHospital Jose Maria Ramos Mejia, Buenos Aires, Argentina.
Carolina PavlovskyFundaleu, Buenos Aires, Argentina.
Gianantonio RostiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy.
Philippe RousselotCentre Hospitalier de Versailles University de Versailles Saint-Quentin-en-Yvelines, Paris, France.
Bo ChaoTakeda Development Center Americas Inc, Cambridge, MA, USA.
Alexander VorogTakeda Development Center Americas Inc, Cambridge, MA, USA.
L Evan ReddickTakeda Development Center Americas Inc, Cambridge, MA, USA.
Niti PatelTakeda Development Center Americas Inc, Cambridge, MA, USA.
Meliessa HennessyTakeda Development Center Americas Inc, Cambridge, MA, USA.
Tammie YehTakeda Development Center Americas Inc, Cambridge, MA, USA.
Jorge CortesGeorgia Cancer Center at Augusta University, Augusta, GA, USA.ORCID http://orcid.org/0000-0002-8636-1071

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The primary analysis of the phase 2 OPTIC trial (NCT02467270) demonstrated optimal benefit:risk with response-based ponatinib dosing (45 mg once daily (QD) reduced to 15 mg QD) upon achieving ≤1% BCR::ABL1

Indexed as

ImidazolesLeukemia, Myeloid, Chronic-PhaseMutationProtein Kinase InhibitorsPyridazinesAdultAgedDNA Mutational AnalysisFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansMaleMiddle AgedYoung AdultFusion Proteins, bcr-ablImidazolesponatinibProtein Kinase InhibitorsPyridazines

Identifiers

PMID42498834
PMCPMC13506327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.